Bassel Nazha, MD
Hematology · Atlanta, GANPI 1215349964
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Exelixis Inc. at 28.4% of the total. 2025 is the largest year on record at $4,662, more than ten times the $91 reported in 2019.
Across 38 payments — averaging $176.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$2K
- Pfizer$2K
- Johnson & Johnson$1K
- Janssen Scientific Affairs, LLC$1K
- Genentech USA, Inc.$91
- Novartis$84
- plus $560 from 16 others
Across 18 payments — averaging $74,829 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas US Technologies$1.1M
- Merck$167K
- Exelixis Inc.$70K
- Astellas Pharma Global Development$44K
What the payments were for
- Consulting fees$3,99860%
- Speaking & faculty fees$1,47022%
- Food & beverage$1,24219%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 5 | $1,905 |
| Pfizer | 3 | $1,545 |
| Johnson & Johnson | 2 | $1,414 |
| Janssen Scientific Affairs, LLC | 1 | $1,110 |
| Genentech USA, Inc. | 1 | $91 |
| Novartis | 3 | $84 |
| AstraZeneca(2 entities) | 3 | $70 |
| Merck | 2 | $56 |
| Daiichi Sankyo Inc. | 2 | $55 |
| Verity Pharmaceuticals Inc. | 1 | $52 |
| GSK | 2 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| AbbVie | 2 | $36 |
| Nuvation Bio Inc. | 1 | $30 |
| Karyopharm Therapeutics Inc. | 1 | $27 |
| Incyte Corporation | 1 | $25 |
| Shield Therapeutics Inc | 1 | $25 |
| Dendreon Pharmaceuticals LLC | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| AVEO Pharmaceuticals, Inc. | 1 | $22 |
| Beone Medicines USA, Inc. | 1 | $20 |
| Array Biopharma Inc | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,710 in reported general payments places this provider in the 55th percentile of 27 hematology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 112 | $1,342,522 |
| Abiraterone Acetate | 235 | $573,624 |
| OrgovyxRelugolix | 205 | $525,375 |
| CabometyxCabozantinib S-Malate | 13 | $378,354 |
| ErleadaApalutamide | 24 | $326,106 |
| LynparzaOlaparib | 13 | $211,503 |
| EliquisApixaban | 12 | $7,999 |
| Bicalutamide | 51 | $1,174 |
| Prochlorperazine Maleate | 77 | $935 |
| Prednisone | 242 | $638 |
| Oxycodone Hcl | 30 | $292 |
| Tamsulosin Hcl | 48 | $280 |
| Mirtazapine | 13 | $205 |
| Dexamethasone | 14 | $198 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $23 | $1,342,522112 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,110 | $573,624235 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $43 | $525,375205 claims |
| Exelixis Inc.Cabometyx | $1,905 | $378,35413 claims |
| Johnson & JohnsonErleada | $1,414 | $326,10624 claims |
| AstraZenecaLynparza | $70 | $211,50313 claims |
| PfizerEliquis | $1,545 | $7,99912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 27 hematology providers in Georgia.
Other hematology in Atlanta
- Sagar LonialAtlanta$1.6M
- Edmund WallerAtlanta$119K
- Craig HofmeisterAtlanta$50K
- Lorraine CafuirAtlanta$41K
- Christine KemptonAtlanta$38K
- Manila GaddhAtlanta$37K
- Kenneth BraunsteinAtlanta$33K
- Duc TranAtlanta$32K
- Mary Jo LechowiczAtlanta$18K
- Martha ArellanoAtlanta$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.